# Current challenges and needs
- Available to more types of patients
- Available for more types of cancer also solid tumors
- Upscaling the car t cells treatment preparation process to lower the costs
- Education programs for medical staff to identify and treat serious side effects
- Guidelines with requirements for medical centers to be able to apply car t cell therapy themselves
CAR T Cell therapy is now only approved to treat two type of blood cancers:
Leukemia: Tisagenlecleucel (Kymriah®)
non-Hodgkin lymphoma : Axicabtagene ciloleucel (Yescarta®)
Results of clinical trials on solid tumors have not been encouraging. But many solid tumors have multiple genomic mutations and the tumor can become resistant to treatment.
The side effects of CAR T cell therapy, especially a condition known as cytokine release syndrome (CRS), can be life-threatening. Therefore EMA and FDA require that hospitals that use CAR T cell therapy have staff certified and trained to recognize and manage CRS.
The process of making CAR T cells is extremely complex. From start to finish, the process may take up two to three weeks.
If the treatment works as desired, the engineered T cells are on duty for the rest of the patient’s life.